Research analysts at Raymond James began coverage on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $6.50 price target on the biotechnology company’s stock. Raymond James’ price objective would indicate a potential upside of 26.46% from the stock’s previous close.

Several other analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $5.50 price objective on shares of ZIOPHARM Oncology in a research note on Thursday, May 9th. BidaskClub cut shares of ZIOPHARM Oncology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 13th. Finally, Zacks Investment Research cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Friday, August 16th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. ZIOPHARM Oncology presently has an average rating of “Buy” and a consensus target price of $6.05.

Shares of NASDAQ:ZIOP traded down $0.09 during mid-day trading on Thursday, hitting $5.14. 1,299,061 shares of the company traded hands, compared to its average volume of 1,813,440. The firm has a market cap of $835.52 million, a P/E ratio of -10.71 and a beta of 2.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.33 and a current ratio of 6.33. ZIOPHARM Oncology has a 52-week low of $1.56 and a 52-week high of $7.25. The firm’s 50 day simple moving average is $5.70 and its 200 day simple moving average is $4.54.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). During the same period in the prior year, the business posted ($0.12) earnings per share. Equities research analysts expect that ZIOPHARM Oncology will post -0.33 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ZIOP. BlackRock Inc. lifted its holdings in ZIOPHARM Oncology by 24.3% in the second quarter. BlackRock Inc. now owns 11,753,413 shares of the biotechnology company’s stock valued at $68,522,000 after buying an additional 2,294,498 shares during the period. Vanguard Group Inc. lifted its holdings in ZIOPHARM Oncology by 11.6% in the second quarter. Vanguard Group Inc. now owns 11,254,728 shares of the biotechnology company’s stock valued at $65,615,000 after buying an additional 1,167,963 shares during the period. Nuveen Asset Management LLC acquired a new position in ZIOPHARM Oncology in the second quarter valued at $4,051,000. Invesco Ltd. acquired a new position in ZIOPHARM Oncology in the second quarter valued at $2,602,000. Finally, SG Americas Securities LLC lifted its holdings in ZIOPHARM Oncology by 1,086.8% in the second quarter. SG Americas Securities LLC now owns 378,669 shares of the biotechnology company’s stock valued at $2,208,000 after buying an additional 346,763 shares during the period. Institutional investors and hedge funds own 40.67% of the company’s stock.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Read More: What is an investor looking for in an SEC filing?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.